Celldex stock price target lowered to $62 at Canaccord on EoE program halt

Celldex Therapeutics (CLDX) experienced multiple analyst price target reductions, including from Canaccord Genuity (to $62 from $64), Wells Fargo (to $38), and H.C. Wainwright (to $42 from $50), following the discontinuation of its eosinophilic esophagitis (EoE) program due to a failed Phase II study. Despite this setback, the company reported positive long-term data for its lead drug, barzolvolimab, in treating chronic spontaneous urticaria (CSU), which remains the primary value driver for investors. These mixed clinical outcomes for barzolvolimab highlight the inherent pipeline risks and opportunities in biopharma, prompting analysts to recalibrate valuations based on the revised outlook.

Analysis

Celldex Therapeutics (CLDX) presents a mixed clinical profile following recent drug development updates. The company's decision to discontinue its eosinophilic esophagitis (EoE) program for the drug barzolvolimab, after a Phase II study failed to show improvements in clinical outcomes, has triggered a series of analyst price target reductions. Canaccord Genuity trimmed its target to $62.00 from $64.00, Wells Fargo reduced its target to $38.00, and H.C. Wainwright lowered its price target to $42.00 from $50.00. However, the impact on valuation appears contained, as Canaccord noted the EoE indication represented only about $2 of its previous price target. This setback contrasts sharply with positive long-term data for barzolvolimab in treating chronic spontaneous urticaria (CSU), its lead program. Favorable results through 76 weeks were presented at a major European conference, reinforcing the view that CSU and chronic inducible urticaria (CIndU) remain the primary value drivers for the company. Analysts have maintained 'Buy' or 'Overweight' ratings, suggesting confidence in the core programs despite the pipeline narrowing.

Key Decisions for Investors

• Investors should focus their due diligence on the commercial potential of the chronic urticaria programs, as the failure in eosinophilic esophagitis has now been priced in by analysts and solidifies urticaria as the core value driver.
• Consider the current stock price of $24.02 in the context of the revised, lower analyst price targets ($38-$62), which may present a recalibrated entry point for those with conviction in the lead drug's success in its primary indications.
• Monitor for any announcements related to new pipeline indications, which management has guided for in 2026, as future growth will depend on successful pipeline expansion beyond urticaria.